On Monday the United States regulator granted fast-track approval for the drug aducanumab, which will be marketed in the US as Aduhelm by biotechnology company Biogen.
The active ingredient in the drug, the aducanumab antibody, was discovered by researchers at the University of Zurich’s Institute for Regenerative Medicine and the Zurich-based biopharmaceutical company Neurimmune.
Alzheimer’s is the most common form of dementia in the elderly, affecting tens of millions of people worldwideExternal link. It is caused by deposits of proteins, called amyloid plaques, in the brain that accumulate over years and damage neurons. It results in progressive memory loss and impairment of learning, orientation, language and planning abilities.
Zurich researchers identified antibodies that neutralise amyloids and “ultimately discovered the substance called aducanumab”, the University of Zurich said in a press release on Monday eveningExternal link.
Neurimmune, a spin-off company from the university founded by two of its professors, says on its websiteExternal link that it is collaborating with Biogen and Japanese company Eisai to develop the drug.
The decision by the US Food and Drug Administration (FDA) to grant the treatment “accelerated approval” has met with some criticism. Drugs can be fast-tracked “to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need”, says the FDAExternal link.
The FDA concluded that the likely benefits of the treatment outweighed the risks of applying a therapy with limited and inconsistent clinical trial data.
This content was published on
A majority of Swiss citizens have open attitudes towards various infertility treatments, including even egg donation, which is currently prohibited.
Reports of Swiss cyber fraud almost doubled in six months
This content was published on
The head of the new Federal Office for Cybersecurity (FOC), Florian Schütz, has presented a new strategy after just over four months in office.
Ecological status of Swiss streams insufficient according to study
This content was published on
Pesticide use and obstructions of waterways have a particularly negative impact on sensitive organisms, completely absent in 70% of streams analysed.
Train line between Brig and Domodossola interrupted
This content was published on
One day after a derailment approximately 15 kilometres from the Swiss border, BLS is running buses for passengers between Preglia and Domodossola, in Italy.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Alzheimer’s vaccine candidate shows promise
This content was published on
The results, published in the latest edition of the Journal of Neuroscience, show that the vaccine impedes the appearance of a protein that is a hallmark of the disease. Beta-amyloid proteins amass in the brain when a person suffers from Alzheimer’s. These so-called plaques are considered to be a typical indicator of the disease, although…
This content was published on
There are far more people with dementia in Switzerland than previously thought – and the number is expected to double over the next 25 years.
This content was published on
But the scientists warn it could be years and plenty of money before any potential application appears on the drug market. It is believed to be the first time that a potent agent against Alzheimer’s has been extracted from a type of cyanobacteria commonly known as ‘pond scum.’ The new compound, nostocarboline, was isolated by…
Study points to shortcomings in dementia diagnosis
This content was published on
The report by the Swiss Alzheimer’s Association also warns that three-quarters of those with the mental disorder are not receiving the proper treatment. The association described the results of the study, published ahead of World Alzheimer’s Day on Tuesday, as “alarming”. It also warned that Switzerland’s health system would face an “enormous challenge” in the…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.